Aerosolized delivery of antifungal agents

Current Fungal Infection Reports

Volumn 4, Issue 2, 2010, Pages 96-102

  Le, Jennifer ^b   Schiller, Daryl S ^a  

^a SAINT BARNABAS MEDICAL CENTER   (United States)

^b NONE

Author keywords

Aerosolized antifungal; Amphotericin B; Antifungal; Caspofungin; Drug safety; Itraconazole; Nebulized antifungal; Voriconazole

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; COLISTIMETHATE; COLISTIN; FLUCONAZOLE; ITRACONAZOLE; PLACEBO; PNEUMOCANDIN DERIVATIVE; VORICONAZOLE; ZANAMIVIR;

AEROSOL; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ASPERGILLOSIS; BAD TASTE; BRONCHOSPASM; COUGHING; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG SOLUBILITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; FUNGAL COLONIZATION; HEART FAILURE; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKEMIA; LUNG ALVEOLUS MACROPHAGE; LUNG ASPERGILLOSIS; LUNG FUNCTION; LUNG TRANSPLANTATION; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY (TOPIC); MYCOSIS; NAUSEA; NEBULIZER; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; PHYSICAL CHEMISTRY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; TASTE DISORDER; TISSUE LEVEL; TONGUE DISEASE; TONGUE NUMBNESS; VOMITING;

EID: 79952186972     PISSN: 19363761     EISSN: 1936377X     Source Type: Journal    
DOI: 10.1007/s12281-010-0011-0     Document Type: Review

References (56)

1. Walsh TJ, Anaissie EJ, Denning DW, et al.: Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008, 46:327-360. This general guideline for the management of aspergillosis includes some information on aerosolized antifungal agents.
2. Mohammad RA, Klein KC: Inhaled amphotericin B for prophylaxis against invasive Aspergillus infections. Ann Pharmacother 2006, 40:2148-2154. (Pubitemid 44954433)
3. Monforte V, Roman A, Gavalda J, et al.: Nebulized amphotericin B concentration and distribution in the respiratory tract of lung-transplanted patients. Transplantation 2003, 759:1571-1574. (Pubitemid 36597298)
4. Drew RH, Dodds Ashley E, Benjamin DK Jr, et al.: Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation 2004, 77:232-237. (Pubitemid 38155752)
5. Myers SE, Devine SM, Topper RL, et al.: A pilot study of prophylactic aerosolized amphotericin B in patients at risk for prolonged neutropenia. Leuk Lymphoma 1992, 8:229-233.
6. Schwartz S, Behre G, Heinemann V, et al.: Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial. Blood 1999, 93:3654-3661. (Pubitemid 29249811)
7. Wingard JR, Kubilis P, Lee L, et al.: Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 1999, 29:1402-1407. (Pubitemid 30022731)
8. Geller DE, Konstan MW, Smith J, et al.: Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr Pulmonol 2007, 42:307-313. This article offers an excellent review of aerosol delivery systems, including nebulizers.
9. Flume P, Klepser ME: The rationale for aerosolized antibiotics. Pharmacotherapy 2002, 22(3 Pt 2):71S-79S.
10. Boe J, Dennis JH, O'Driscoll BR, et al.: European Respiratory Society guidelines on the use of nebulizers. Eur Respir J 2001, 18 (1):228-242. (Pubitemid 32717452)
11. Dolovich MB, Ahrens RC, Hess DR, et al.: Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest 2005, 127:335-371. (Pubitemid 41724594)
12. Kuhn RJ: Pharmaceutical considerations in aerosol drug delivery. Pharmacotherapy 2002, 22(3 Pt 2):80S-85S.
13. Bayat M, Cook AM: Intrapulmonary administration of medications. J Neurosci Nurs 2004, 36:231-235.
14. Campbell PW 3rd, Saiman L: Use of aerosolized antibiotics in patients with cystic fibrosis. Chest 1999, 116(3):775-788.
15. Wood GC, Boucher BA: Aerosolized antimicrobial therapy in acutely ill patients. Pharmacotherapy 2000, 20:166-181. (Pubitemid 30073837)
16. Hess D, Fisher D, Williams P, et al.: Medication nebulizer performance. Effects of diluent volume, nebulizer flow, and nebulizer brand. Chest 1996, 110:498-505.
17. Dhand R: The role of aerosolized antimicrobials in the treatment of ventilator-associated pneumonia. Respir Care 2007, 52:866-884.
18. Lewis RE, Liao G, Hou J, et al.: Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2007, 51:1253-1258. (Pubitemid 46586802)
19. Olson JA, Adler-Moore JP, Schwartz J, et al.: Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model. Antimicrob Agents Chemother 2006, 50:2122-2131. (Pubitemid 43807534)
20. Vogelsinger H, Weiler S, Djanani A, et al.: Amphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersion. J Antimicrob Chemother 2006, 57:1153-1160. (Pubitemid 44644419)
21. Andes D: Pharmacokinetics and pharmacodynamics of antifungals. Infect Dis Clin North Am 2006, 20:679-697.
22. Ruijgrok EJ, Fens MH, Bakker-Woudenberg IA, et al.: Nebulized amphotericin B combined with intravenous amphotericin B in rats with severe invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2006, 50:1852-1854.
23. Diot P, Rivoire B, Le Pape A, et al.: Deposition of amphotericin B aerosols in pulmonary aspergilloma. Eur Respir J 1995, 8:1263-1268.
24. Gryn J, Goldberg J, Johnson E, et al.: The toxicity of daily inhaled amphotericin B. Am J Clin Oncol 1993, 16:43-46. (Pubitemid 23074780)
25. Ruijgrok EJ, Fens MH, Bakker-Woudenberg IA, et al.: Nebulization of four commercially available amphotericin B formulations in persistently granulocytopenic rats with invasive pulmonary aspergillosis: evidence for long-term biological activity. J Pharm Pharmacol 2005, 57:1289-1295. (Pubitemid 41545894)
26. Corcoran TE, Venkataramanan R, Mihelc KM, et al.: Aerosol deposition of lipid complex amphotericin-B (Abelcet) in lung transplant recipients. Am J Transplant 2006, 6:2765-2773. (Pubitemid 44571699)
27. Beyer J, Schwartz S, Barzen G, et al.: Use of amphotericin B aerosols for the prevention of pulmonary aspergillosis. Infection 1994, 22:143-148.
28. Koizumi T, Kubo K, Kaneki T, et al.: Pharmacokinetic evaluation of amphotericin B in lung tissue: lung lymph distribution after intravenous injection and airspace distribution after aerosolization and inhalation of amphotericin B. Antimicrob Agents Chemother 1998, 42:1597-1600. (Pubitemid 28311548)
29. Lambros MP, Bourne DW, Abbas SA, Johnson DL: Disposition of aerosolized liposomal amphotericin B. J Pharm Sci 1997, 86:1066-1069.
30. Niki Y, Bernard EM, Schmitt HJ, et al.: Pharmacokinetics of aerosol amphotericin B in rats. Antimicrob Agents Chemother 1990, 34:29-32. (Pubitemid 20019959)
31. Monforte V, Ussetti P, Lopez R, et al.: Nebulized liposomal amphotericin B prophylaxis for Aspergillus infection in lung transplantation: pharmacokinetics and safety. J Heart Lung Transplant 2009, 28:170-175.
32. Vyas SP, Quraishi S, Gupta S, Jaganathan KS: Aerosolized liposome-based delivery of amphotericin B to alveolar macrophages. Int J Pharm 2005, 296:12-25. (Pubitemid 40693368)
33. Alvarez CA, Wiederhold NP, McConville JT, et al.: Aerosolized nanostructured itraconazole as prophylaxis against invasive pulmonary aspergillosis. J Infect 2007, 55:68-74. (Pubitemid 46888077)
34. Hoeben BJ, Burgess DS, McConville JT, et al.: In vivo efficacy of aerosolized nanostructured itraconazole formulations for prevention of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2006, 50:1552-1554.
35. McConville JT, Overhoff KA, Sinswat P, et al.: Targeted high lung concentrations of itraconazole using nebulized dispersions in a murine model. Pharm Res 2006, 23:901-911. (Pubitemid 43781398)
36. Vaughn JM, McConville JT, Burgess D, et al.: Single dose and multiple dose studies of itraconazole nanoparticles. Eur J Pharm Biopharm 2006, 63:95-102. (Pubitemid 43776206)
37. Capitano B, Potoski BA, Husain S, et al.: Intrapulmonary penetration of voriconazole in patients receiving an oral prophylactic regimen. Antimicrob Agents Chemother 2006, 50:1878-1880.
38. Tolman JA, Nelson NA, Son YJ, et al.: Characterization and pharmacokinetic analysis of aerosolized aqueous voriconazole solution. Eur J Pharm Biopharm 2009, 72:199-205.
39. Kurtz MB, Bernard EM, Edwards FF, et al.: Aerosol and parenteral pneumocandins are effective in a rat model of pulmonary aspergillosis. Antimicrob Agents Chemother 1995, 39:1784-1789.
40. Wong-Beringer A, Lambros MP, Beringer PM, Johnson DL: Suitability of caspofungin for aerosol delivery: physicochemical profiling and nebulizer choice. Chest 2005, 128:3711-3716. (Pubitemid 41698718)
41. Conte RA, Kleyman SM, Klein V, et al.: Characterization of a de novo t(Y;9) (q11.2;q22) by FISH technique. Ann Genet 1996, 39:10-15. (Pubitemid 26143478)
42. Safdar A, O'Brien S, Kouri IF: Efficacy and feasibility of aerosolized amphotericin B lipid complex therapy in caspofungin breakthrough pulmonary zygomycosis. Bone Marrow Transplant 2004, 34:467-468. (Pubitemid 39232379)
43. Erjavec Z, Woolthuis GM, de Vries-Hospers HG, et al.: Tolerance and efficacy of amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in haematological patients. Eur J Clin Microbiol Infect Dis 1997, 16:364-368. (Pubitemid 27271824)
44. Behre GF, Schwartz S, Lenz K, et al.: Aerosol amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in neutropenic cancer patients. Ann Hematol 1995, 71:287-291. (Pubitemid 26002066)
45. Alexander BD, Dodds Ashley ES, Addison RM, et al.: Non-comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2006, 8:13-20.
46. Rijnders BJ, Cornelissen JJ, Slobbe L, et al.: Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis 2008, 46:1401-1408. This study of patients with hematologic diseases demonstrated significant reduction in invasive pulmonary aspergillosis with the nebulization of L-AmB. This is the second-largest randomized, placebo-controlled trial of aerosolized amphotericin B products.
47. Monforte V, Roman A, Gavalda J, et al.: Nebulized amphotericin B prophylaxis for Aspergillus infection in lung transplantation: study of risk factors. J Heart Lung Transplant 2001, 20:1274-1281. (Pubitemid 34017312)
48. Husain S, Paterson DL, Studer S, et al.: Voriconazole prophylaxis in lung transplant recipients. Am J Transplant 2006, 6:3008-3016.
49. Palmer SM, Drew RH, Whitehouse JD, et al.: Safety of aerosolized amphotericin B lipid complex in lung transplant recipients. Transplantation 2001, 72:545-548. (Pubitemid 32769650)
50. Borro JM, Sole A, de la Torre M, et al.: Efficiency and safety of inhaled amphotericin B lipid complex (Abelcet) in the prophylaxis of invasive fungal infections following lung transplantation. Transplant Proc 2008, 40:3090-3093.
51. FDA information for healthcare professionals: Colistimethate. Available at http://www.fda.gov/downloads/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ ucm124894.pdf. Accessed January 26, 2010.
52. GlaxoSmithKline: Important drug warning - Relenza inhalation powder must not be nebulized. Available at http://www.fda.gov/ downloads/Safety/MedWatch/ SafetyInformation/SafetyAlertsfo rHumanMedicalProducts/UCM186224.pdf. Accessed January 26, 2010.
53. Knechtel SA, Klepser ME: Safety of aerosolized amphotericin B. Expert Opin Drug Saf 2007, 6:523-532. This article offers an excellent review on the safety of aerosolized amphotericin B.
54. Lowry CM, Marty FM, Vargas SO, et al.: Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections following lung transplantation: a retrospective study. Transpl Infect Dis 2007, 9:121-125. (Pubitemid 46669088)
55. Slobbe L, Boersma E, Rijnders BJ: Tolerability of prophylactic aerosolized liposomal amphotericin-B and impact on pulmonary function: data from a randomized placebo-controlled trial. Pulm Pharmacol Ther 2008, 21:855-859.
56. Nikolaizik WH, Trociewicz K, Ratjen F: Bronchial reactions to the inhalation of high-dose tobramycin in cystic fibrosis. Eur Respir J 2002, 20:122-126. (Pubitemid 34822933)